Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

ISIS PHARMACEUTICALS, INC. (ISIS)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

ISIS Pharmaceuticals, Inc. : Law Offices of Howard G. Smith Announces Class Action Lawsuit Against ISIS Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/26/2013 | 08:35pm CEST

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all purchasers of the common stock of ISIS Pharmaceuticals, Inc. ("ISIS" or the "Company") (NASDAQ:ISIS) between March 29, 2012 and October 15, 2012, inclusive (the "Class Period").

ISIS engages in the discovery and development of drugs utilizing antisense technology, primarily to treat cardiovascular, metabolic, severe and rare diseases, as well as cancer. The Complaint alleges that throughout the Class Period the Company and certain of its executive officers issued materially false and misleading statements regarding the safety and efficacy of the Company's flagship product, Kynamro (mipomersen sodium), for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Specifically, the Complaint alleges that defendants, through a series of materially false and misleading statements regarding the safety and efficacy of the product, and reportedly positive results from Kynamro's clinical trials, conditioned investors to believe that Kynamro would receive approval from the U.S. Food and Drug Administration (FDA).

On October 16, 2012 the FDA published a clinical briefing document raising concerns regarding the safety and efficacy of Kynamro, noting among other things, abnormal growths or neoplasms developed in 3.1% of patients treated with Kynamro, as compared to only 0.9% of patients who took a placebo; that the data submitted by the Company was limited by a small sample size and a short treatment time, and that during the clinical testing two patients treated with Kynamro died of heart attacks and another patient died of acute liver failure. The FDA report concluded that this "imbalance in neoplasms will need to be assessed further in on-going and future studies and post-marketing (if approved)," and that "the potential for a contributing effect of mipomersen cannot be ruled out" in the patient deaths. As a result of these disclosures, ISIS shares declined nearly 22%, to close at $10.27 on October 16, 2012.

No class has yet been certified in this action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased ISIS common stock during the Class Period, you have certain rights, and have until February 26, 2013 to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
04/21IONIS PHARMACEUTICALS : to get $1 billion cash in expanded deal with Biogen
AQ
04/20IONIS PHARMACEUTICALS : Gains on Biogen Hookup
AQ
04/20IONIS PHARMACEUTICALS : to get $1 billion cash in expanded deal with Biogen
AQ
04/20BIOGEN : and Ionis Expand Strategic Collaboration to Develop Drug Candidates for..
BU
04/19IONIS PHARMACEUTICALS : and AstraZeneca Advance New Drug for NASH
AQ
04/10IONIS PHARMACEUTICALS : earns $30 million upfront in third deal with AstraZeneca
AQ
04/02Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
AQ
04/02Why Alnylam Pharmaceuticals, Inc. Is Tanking Today
AQ
03/28IONIS PHARMACEUTICALS : Provides Corporate Update at 2018 Annual Meeting of Stoc..
AQ
03/23IONIS PHARMACEUTICALS : Provides Corporate Update at 2018 Annual Meeting of Stoc..
PR
More news
News from SeekingAlpha
2015Game Plan For The Week - Cramer's Mad Money (12/18/15) 
2015PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr.. 
2015Isis Pharma has had enough, name changed to Ionis Pharmaceuticals 
2015Bear Afoot? No Recession Needed For A Possible Sighting 
2015PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui.. 
Financials ($)
Sales 2018 606 M
EBIT 2018 -37,8 M
Net income 2018 -50,8 M
Finance 2018 12,3 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 2 205,00
EV / Sales 2018 10,0x
EV / Sales 2019 8,09x
Capitalization 6 085 M
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 13
Average target price 62,0 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
Brett P. Monia Chief Operating Officer
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
Sanjay Bhanot Chief Medical Officer
B. Lynne Parshall Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%6 085
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.09%14 493
NEKTAR THERAPEUTICS44.36%13 873